Radiotherapy in Metastatic Bladder Cancer

Sophie Ashley, Ananya Choudhury, Peter Hoskin, Yeepei Song, Priyamvada Maitre

Research output: Contribution to journalArticlepeer-review


Metastatic bladder cancer is associated with considerable morbidity and poor survival. Alongside the advances in systemic treatment with immune checkpoint inhibitors, fibroblast growth receptor inhibitors and antibody-drug conjugates, there remains an important role for palliative radiotherapy. It is an effective and accessible treatment for alleviation of haematuria and pain due to the primary and metastatic disease. It is further being explored in combination with targeted systemic therapies for its immunomodulatory potential. With growing recognition of oligometastatic disease state at diagnosis, response, or progression, radiotherapy also offers a means to consolidate response by ablating residual or resistant lesions. Experience with other primary cancers support positive impact of radiotherapy on disease control, quality of life, and survival in metastatic stage, without significant adverse effects. This review looks at the available and emerging evidence for the role of radiotherapy in various clinical stages of metastatic bladder cancer.
Original languageEnglish
JournalWorld Journal of Urology
Issue number47
Publication statusPublished - 20 Jan 2024


  • metastatic bladder cancer
  • oligometastatic bladder cancer
  • bladder radiotherapy
  • palliative radiotherapy


Dive into the research topics of 'Radiotherapy in Metastatic Bladder Cancer'. Together they form a unique fingerprint.

Cite this